The "Abu Dhabi Stem Cells Centre" has achieved a new milestone through one of its clinical trials studying the use of phototherapeutic immunotherapy in treating patients with multiple sclerosis. The study evaluates the efficacy and safety of phototherapeutic immunotherapy for multiple sclerosis, noting that this treatment is already used for certain types of cancer, autoimmune diseases, and organ transplant rejection. The center is exploring its use to alleviate symptoms of multiple sclerosis by restoring the patient's immune balance.
The center revealed that this clinical trial involves a resident of the country who was diagnosed with multiple sclerosis in 2019, when he was experiencing worsening symptoms over time, including difficulty walking, balance issues, speech stuttering, and cognitive and visual impairments. After six months of phototherapeutic immunotherapy, there was a significant improvement in the patient's mobility and eyesight, along with an increased ability to speak clearly. Balance issues decreased, as observed in examinations over a three-month period.
In 2022, the "Use of Phototherapeutic Immunotherapy in Treating Patients with Multiple Sclerosis at the Abu Dhabi Stem Cells Centre" trial received approval from the Department of Health Abu Dhabi. Following this, a number of patients with secondary progressive multiple sclerosis or relapsing multiple sclerosis were enrolled to receive this treatment, and the study was registered in the global clinical trials registry.
